Search Results

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) today reported financial results for the first quarter ended March 31, 2024, and highlighted select corporate achievements.

Innoviva, Inc., a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics, and a portfolio of strategic investments in healthcare assets, announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Monday, June 10, 2024 at 1:20 p.m. Eastern Time.

Innoviva, Inc., a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics, and a portfolio of strategic investments in healthcare assets, announced that Pavel Raifeld, Chief Executive Officer, will present at the BofA Securities Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024 at 9:20 a.m.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”) today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, “Innoviva”), Armata’s largest shareholder.

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership at the European Society of Clinical Microbiology and Infectious Disease Global Congress taking place April 27-30, 2024, in Barcelona, Spain.

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.

Zai Lab Limited and Innoviva Specialty Therapeutics announced that China’s National Medical Products Administration has approved Zai Lab’s New Drug Application for XACDURO® for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.